Prinzide

This page contains recent news articles, when available, and an overview of Prinzide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Prinzide
(when available)

Pharmacology and use:
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension, congestive heart failure (CHF), postmyocardial infarction, and diabetic nephropathy or retinopathy. Although it is the lysine ester of enalaprilat, the active form of the prodrug enalapril, lisinopril is active unchanged. For the treatment of hypertension, heart failure and acute myocardial infarction. It may be used alone or in combination with thiazide diuretics

Mechanism Of Action:
Lisinopril competes with angiotensin I for its binding site on the angiotensin-converting enzyme (ACE), an enzyme which converts angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II plasma levels result in decreased blood pressure and increased plasma renin activity. Baroreceptor reflex mechanisms, stimulated by the fall in blood pressure, release kininase II, an enzyme identical to ACE that degrades bradykinin, a vasodilator.

News Articles on Lisinopril

FDA Safety Changes: Prinzide, Avinza, Epogen  -  Jan 5, 2006
Jan. 5, 2006 -- The US Food and Drug Administration (FDA) approved in October 2005 safety labeling revisions to advise that the lisinopril component of ... Medscape

Lupin gets US FDA approval for Lisinopril-HCTZ Tablets  -  Sep 28, 2006
Inc. under the brand name Prinzide. The total sales for the year ending July 2006 were approximately U$ 106 million, per IMS Health. ... Equity Bulls

L'usine de Kirkland ferme, 235 emplois sont perdus au Canada  -  Nov 29, 2005
Le Prinivil, le Prinzide, le Vasotec, le Vasoretic et le Mevacor, des médicaments traitant l'hypertension et les maladies cardiaques, étaient fabriqués à ... Le Devoir - Le Devoir (Abonnement)

Connecticut Workers' Compensation Decisions - WABNO v. CITY OF …  -  Sep 12, 2008
Dr. Borkowski opined that the medication Prinzide, which the claimant was taking in ... She found the claimant was on Prinzide at the time of his May 6, ... Pay-Per-View - Connecticut Workers' Compensation... - Loislaw

Article: Second quarter drives Novartis towards record. - The Evening...  -  Jul 14, 2005
Business/Health Editors Eon Labs, Inc. (Nasdaq:ELAB) announced ... hypertension treatment Prinzide(R)(a). Eon Labs approval is for the same strengths ... Pay-Per-View - Evening Standard - HighBeam Research

Company Profile Report  -  Apr 5, 2008
Vaseretic (Enalapril Maleate/Hydrochlorothiazide); Prinzide (Lisinopril/Hydrochlorothiazide). Angiotensin II Receptor Antagonists ... $50.00 - Revere Reports - Revere

Federal Register 2008 - 73 FR 77723 Determination That RUBRAMIN PC …  -  Dec 19, 2008
Inc., tromethamine) Tablets, 340 Kingsland St., 10 mg Nutley, NJ 07110-1199 NDA 19-778 PRINZIDE Merck Research (hydrochlorothiazide and Laboratories, ... Pay-Per-View - Federal Register 2008 - Loislaw

INDIA'S AUROBINDO GETS US FDA APPROVAL FOR LISINOPRIL …  -  Mar 17, 2006
Lisinopril and Hydrochlorothiazide tablets is the generic version of Prinzide tablets, 10 / 12.5 mg, 20 / 12.5 mg, and 20 / 25 mg of Merck research ... $4.95 - AsiaPulse News - ECNext

Article: Novartis snaps up German rival. - The Evening Standard...  -  Feb 21, 2005
Business/Health Editors Eon Labs, Inc. (Nasdaq:ELAB) announced ... hypertension treatment Prinzide(R)(a). Eon Labs approval is for the same strengths ... Pay-Per-View - Evening Standard - HighBeam Research

Article: Novartis creates a drugs giant with [pounds sterling]3.9bn...  -  Feb 21, 2005
Business/Health Editors Eon Labs, Inc. (Nasdaq:ELAB) announced ... hypertension treatment Prinzide(R)(a). Eon Labs approval is for the same strengths ... Pay-Per-View - Evening Standard - HighBeam Research

Press Release: Lupin Receives Final Approval for Lisinopril-HCTZ …  -  Sep 28, 2006
Lupin's Lisinopril-HCTZ tablets are the AB-rated generic equivalent of Prinzide(R) Tablets of Merck & Co., Inc. and is indicated for the treatment of ... Pay-Per-View - PR Newswire - HighBeam Research

Competitors by Product Report  -  Mar 29, 2008
Merck & Co., Inc. (MRK) Products:. Prinzide (Lisinopril/Hydrochlorothiazide); Vaseretic (Enalapril Maleate/Hydrochlorothiazide) ... $75.00 - Revere Reports - Revere

Brand Names/Synonyms:
Prinzide is also known by the following brand names and/or synonymsAcercomp; BL 19; BL-19; HSDB 6852; Inhibril; Linopril; Lisinopril; Lisinopril Dihydrate; Lisipril; Lysinopril; Noperten; Presiten; Prinivil; Prinzide; Renacor; Sinopril; Zestoretic; Zestril

Drug Category:
Prinzide is categorized under the following by the FDA: Cardiotonic Agents; Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA03

Dosage Forms:
Tablets

Absorption:
Approximately 25%, but widely variable between individuals (6 to 60%)

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
1-[6-amino-2-(1-carboxy-3-phenyl-propyl)amino-hexanoyl]pyrrolidine-2-carboxylic acid dihydrate





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy